Cell and Gene Therapy Supply Chain/Logistics Market Size, Share & Trends Analysis Report By Application area, By Type of software solution, By Mode of Deployment, By End-user (Biobank, Cell therapy lab, Hospital, Research institute, Commercial organization) , By Scale of Operation, By Region, And By Segment Forecasts, 2025-2034
Cell and Gene Therapy Supply Chain/Logistics Market Size is valued at 1.5 Billion in 2024 and is predicted to reach 4.4 Billion by the year 2034 at a 11.9 % CAGR during the forecast period for 2025-2034.

Global Cell and Gene Therapy Supply Chain/Logistics provides customizable services to support any stage of the supply chain, from the point of patient identification through cell harvest, therapeutic intervention, and long-term outcomes data collection. Cell and gene therapies are spearheading a new era in medicine, offering treatments specifically designed to target individual patients' needs. As therapies become more personalized, the need for robust and adaptable supply chain services is skyrocketing. From the procurement of patient-specific materials to the delivery of customized treatments, supply chain services are adapting to ensure seamless coordination of these complex processes. Providing personalized therapeutics along with smart packaging is a key challenge in this market.
Competitive Landscape:
1. Marken, a UPS Company
2. World Courier, a Cencora Company
3. DHL Global Forwarding / DHL Life Sciences & Healthcare
4. Kuehne + Nagel International AG (QuickSTAT)
5. Cryoport Systems, Inc.
6. UPS Healthcare (United Parcel Service, Inc.)
7. FedEx Express / FedEx Healthcare
8. Vineti, Inc.
9. TrakCel Ltd.
10. SAP SE
The challenges and needs of cell and gene therapy supply chains increase the need for more advanced IT systems. Most pharmaceutical companies are collaborating with IT companies to make services automated and less complex. Modern technology platforms for supply chain data management can help you control, manage, and monitor your supply chains in just a few clicks. For instance, Marken is developing technologies designed to address complex logistics and provide optimal supply chain solutions for the fast-growing cell and gene therapies market. The constant improvements in the cell and gene therapy (CGT) supply chain management services are expected to propel the Cell and Gene Therapy Supply Chain/Logistics market growth over the forecast period.
The increasing need for cell and gene therapies, developments in the real-time supply chain operations, and the rising number of clinical trials is likely to evolve the Cell and Gene Therapy Supply Chain/Logistics market at a considerable rate in the next few years. Furthermore, advanced medical technologies, increasing customizable facilities, improving quality and efficacy of CGT supply chain services, and novel supply chain service innovations by pharmaceutical companies enhance the market growth. However, the high investment cost required for CGT supply chain services, lack of standard therapy protocols, and complex procedures hinder the market growth.
Market Segmentation
Segmentation of Cell and Gene Therapy Supply Chain/Logistics market includes Application area (Donor eligibility assessment, Sample collection, Manufacturing, Logistics, Patient verification and treatment follow-up), Type of software solution (Cell orchestration platform, Enterprise manufacturing system, Inventory management system, Laboratory information management system, Logistics management system, Patient management system, Quality management system, Tracking and tracing system), Mode of Deployment (Cloud-based solution, On-premises solution), End-user (Biobank, Cell therapy lab, Hospital, Research institute, Commercial organization). Regionally, the Cell and Gene Therapy Supply Chain/Logistics market can be divided into North America, Europe, Latin America, Asia-Pacific, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, improved CGT supply chain services efficiency, and the fast adoption of advanced technologies.
Recent Development
- In June 2023, RoslinCT and Lykan Bioscience, prominent CDMOs in the Cell and Gene Therapy sector, have merged to form a consolidated enterprise that will function under the RoslinCT name. The integration, overseen by GHO Capital, a worldwide investment business, seeks to build a leading participant in the Advanced Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) sector.
- In October 2023, Be The Match BioTherapies and Cryoport announced a new strategic partnership. The collaboration will expand the capabilities of IntegriCell™, a standardized bioprocessing, cryopreservation and distribution solution for the global cell therapy market. With cryopreservation facilities in the U.S. and EU, IntegriCell™ is poised to support decentralized and centralized manufacturing models, enabling and accelerating patient access to innovative new therapies.
Cell and Gene Therapy Supply Chain/Logistics Market Report Scope:
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 1.5 Billion |
| Revenue Forecast In 2034 | USD 4.4 Billion |
| Growth Rate CAGR | CAGR of 11.9 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Application area, Type of software solution, Mode of Deployment, End-user, Scale of operation |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Be The Match BioTherapies, MAK-SYSTEM, Cryoport, Brooks Life Sciences, Lykan Bioscience, Clarkston Consulting, SAP, Hypertrust Patient Data Care, Haemonetics, MasterControl, TraceLink, SAVSU Technologies, TrakCel, Title21 Health Solutions, sedApta Group, Vineti, Stafa Cellular Therapy, Thermo Fisher Scientific(Patheon), McKesson, Biocair, Marken(UPS Company), Modality Solutions, Almac, Arvato Supply Chain Solutions SE, Catalent, Inc, BioLife Solutions, Inc, Biostor Ltd, Yourway Biopharma Services Company, Atelerix Ltd |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Market Segmentation:
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Application Area
· Donor & Patient Enrollment
· Sample Collection & Processing
· Manufacturing & Quality Operations
· Cryogenic Logistics & Distribution
· Patient Administration & Follow-Up
· Data Integration & Regulatory Compliance

Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Type of Software Solution
· Cell Orchestration Platforms (COI/COC)
· Manufacturing Execution Systems (MES)
· Inventory & Material Management Systems
· Laboratory Information Management Systems (LIMS)
· Logistics & Supply Chain Management Platforms
· Patient & Donor Management Systems
· Quality & Compliance Management Systems (QMS)
· Tracking, Traceability & Analytics Platforms
· Integrated Data / Interoperability Layers
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on End-User
· Biobanks & Repository Operators
· Cell Therapy Manufacturing Facilities
· Hospitals & Transplant Centers
· Research Institutes / Academic Medical Centers
· Biopharma & CGT Developers
· CDMOs / CROs
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Scale of Operation
- Clinical Scale
- Commercial Scale
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Type of Deployment
· Cloud-Based
· On-Premises
· Hybrid
· SaaS Subscription
Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2025 to 2034 based on Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2025 to 2034
- U.S.
- Canada
Europe Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2025 to 2034
- Germany
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2025 to 2034
- India
- China
- Japan
- South Korea
- Australia & New Zealand
Latin America Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2025 to 2034
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa Cell and Gene Therapy Supply Chain/Logistics market revenue (US$ Million) by Country, 2025 to 2034
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Landscape
- Company Overview
- Financial Performance
- Key Development
- Latest Strategic Developments
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cell and Gene Therapy Supply Chain/Logistics Market Size is valued at 1.5 Billion in 2024 and is predicted to reach 4.4 Billion by the year 2034
Cell and Gene Therapy Supply Chain/Logistics Market is expected to grow at an 11.9 % CAGR during the forecast period for 2025-2034
Be The Match BioTherapies, MAK-SYSTEM, Cryoport, Brooks Life Sciences, Lykan Bioscience, Clarkston Consulting, SAP, Hypertrust Patient Data Care
Application area, Type of software solution, Mode of Deployment, End-user, Scale of operation are the key segments of the Cell and Gene Therapy Supply Chain/Logistics
North American region is leading the Cell and Gene Therapy Supply Chain/Logistics Market.